GDF15/GDF11 Signaling in Neurodegeneration

GDF15/GDF11 Signaling in Neurodegeneration

Overview

Growth Differentiation Factor 15 (GDF15) and GDF11 are members of the TGF-β (Transforming Growth Factor beta) superfamily that have emerged as critical regulators of energy homeostasis, stress responses, and more recently, neuroprotection. Originally characterized for their roles in embryonic development, these cytokines have gained significant attention for their involvement in aging, metabolic disorders, and neurodegenerative diseases.

GDF15 and GDF11 Biology

Structural Features

GDF15 and GDF11 are secreted cytokines belonging to the TGF-β superfamily. They share structural homology with other family members but have distinct biological functions: [@wang2023]

• GDF15: Also known as MIC-1 (Macrophage Inhibitory Cytokine-1), NAG-1 (Non-Steroidal Anti-Inflammatory Drug-Activated Gene), and PTGFB (Placental Transforming Growth Factor Beta)
• GDF11: Known as BMP-11 (Bone Morphogenetic Protein-11), involved in embryonic patterning and tissue development

Both proteins are synthesized as precursor molecules that undergo proteolytic cleavage to produce the mature, biologically active form. [@johnen2023]

Expression Patterns

GDF15 is expressed in virtually all tissues but is highly expressed in: [@yatsiv2024]

• Placenta
• Liver
• Kidney
• Brain (particularly in regions involved in energy homeostasis)
• Adipose tissue
• Muscle

GDF11 expression is more restricted, with high levels in: [@schmidt2023]

• Developing nervous system
• Skeletal muscle
• Heart
• Pancreas

TGF-β Family Relationships

...

GDF15/GDF11 Signaling in Neurodegeneration

Overview

Growth Differentiation Factor 15 (GDF15) and GDF11 are members of the TGF-β (Transforming Growth Factor beta) superfamily that have emerged as critical regulators of energy homeostasis, stress responses, and more recently, neuroprotection. Originally characterized for their roles in embryonic development, these cytokines have gained significant attention for their involvement in aging, metabolic disorders, and neurodegenerative diseases.

GDF15 and GDF11 Biology

Structural Features

GDF15 and GDF11 are secreted cytokines belonging to the TGF-β superfamily. They share structural homology with other family members but have distinct biological functions: [@wang2023]

• GDF15: Also known as MIC-1 (Macrophage Inhibitory Cytokine-1), NAG-1 (Non-Steroidal Anti-Inflammatory Drug-Activated Gene), and PTGFB (Placental Transforming Growth Factor Beta)
• GDF11: Known as BMP-11 (Bone Morphogenetic Protein-11), involved in embryonic patterning and tissue development

Both proteins are synthesized as precursor molecules that undergo proteolytic cleavage to produce the mature, biologically active form. [@johnen2023]

Expression Patterns

GDF15 is expressed in virtually all tissues but is highly expressed in: [@yatsiv2024]

• Placenta
• Liver
• Kidney
• Brain (particularly in regions involved in energy homeostasis)
• Adipose tissue
• Muscle

GDF11 expression is more restricted, with high levels in: [@schmidt2023]

• Developing nervous system
• Skeletal muscle
• Heart
• Pancreas

TGF-β Family Relationships

GDF15 and GDF11 belong to the TGF-β superfamily but represent a distinct branch separate from classical TGF-βs (TGF-β1, TGF-β2, TGF-β3) and BMPs (Bone Morphogenetic Proteins). They share: [@tanaka2024]

• Type I and Type II receptor binding
• SMAD-dependent signaling pathways
• Dimeric structure

Key distinguishing features: [@hsiao2023]

• GDF15 signals primarily through the GFRAL-RET receptor complex
• GDF11 signals through activin type I and type II receptors

GFRAL/RET Receptor Complex

Receptor Structure

GDF15 exerts its effects primarily through a unique receptor complex: [@muller2023]

• GFRAL (Glial Cell Line-Derived Neurotrophic Factor Receptor Alpha-Like): The primary binding receptor, expressed predominantly in the brainstem
• RET (Rearranged During Transfection): The co-receptor that initiates intracellular signaling

This receptor complex was identified as the canonical receptor for GDF15 in 2017, explaining its effects on energy balance and body weight. [@kempf2024]

Signaling Pathways

Upon GDF15 binding to GFRAL: [@wiedmann2023]

RET autophosphorylation

Activation of PI3K-AKT pathway

MAPK/ERK pathway activation

PLCγ pathway activation

These downstream pathways regulate: [@liu2024]

• Cell survival
• Metabolic regulation
• Neuroprotection

Stress-Regulated Expression

Cellular Stress

GDF15 expression is dramatically upregulated by various cellular stresses:

• Oxidative stress: ROS accumulation induces GDF15 transcription via NRF2
• Endoplasmic reticulum stress: UPR pathways activate GDF15 expression
• Mitochondrial dysfunction: Impaired mitochondrial function increases GDF15
• Inflammatory cytokines: IL-6, TNF-α, and IL-1β stimulate GDF15 expression

Systemic Stress

GDF15 serves as a biomarker of systemic stress:

• Tissue injury
• Cancer
• Cardiovascular disease
• Metabolic syndrome

Anorexia/Cachexia Connection

Appetite Regulation

GDF15 acts as a potent anorexigenic (appetite-suppressing) cytokine:

• Activates GFRAL-expressing neurons in the area postrema and nucleus tractus solitarius
• Induces satiety signals
• Reduces food intake
• Promotes weight loss

Cachexia

Elevated GDF15 levels are associated with cancer cachexia and wasting syndromes:

• Marker of cachexia severity
• Therapeutic target for cachexia management
• Correlates with mortality in chronic diseases

Neuroprotective Effects

Neuronal Survival

GDF15 exerts neuroprotective effects through multiple mechanisms:

Anti-apoptotic effects: Activates PI3K-AKT pathway to inhibit apoptosis

Antioxidant properties: Upregulates NRF2-dependent antioxidant genes

Anti-inflammatory effects: Modulates microglial activation

Mitochondrial protection: Preserves mitochondrial function

Synaptic plasticity: Supports synaptic formation and function

Neurogenesis

GDF11 has been shown to:

• Promote neurogenesis in the subventricular zone
• Enhance neuronal differentiation
• Improve cognitive function in aging

Anti-Aging Potential

Circulating GDF15 and Aging

• GDF15 levels increase with age in humans and mice
• Higher baseline GDF15 predicts mortality
• Associated with age-related diseases

Longevity

• GDF15 overexpression extends lifespan in model organisms
• GDF15 deficiency accelerates age-related phenotypes
• Therapeutic potential for anti-aging interventions

Alzheimer's Disease Mechanisms

GDF15 in AD

• Elevated GDF15 levels in AD patients correlate with disease severity
• Associated with hippocampal atrophy
• Linked to cognitive decline

Therapeutic Implications

• GDF15 modulation may affect amyloid and tau pathology
• GDF15's metabolic effects may influence AD progression
• GFRAL agonists under investigation for cognitive enhancement

Parkinson's Disease Mechanisms

GDF15 in PD

• Increased GDF15 in PD patients
• Associated with motor severity
• Correlates with non-motor symptoms

Neuroprotection Potential

• Protects dopaminergic neurons from oxidative stress
• May influence alpha-synuclein pathology
• GFRAL signaling supports neuronal survival

ALS Mechanisms

GDF15 in ALS

• Elevated GDF15 in ALS patients
• Correlates with disease progression
• Potential biomarker for disease staging

Therapeutic Targeting

• GDF15 axis modulation as therapeutic strategy
• GFRAL agonists may support motor neuron survival

Therapeutic Strategies

GFRAL Agonists

• Small molecule GFRAL agonists in development
• GDF15 analogs for metabolic applications
• RET-targeted approaches

GDF15 Neutralization

• Anti-GDF15 antibodies for cachexia treatment
• Soluble receptor constructs
• siRNA approaches

Combination Approaches

• GDF15 modulation with standard-of-care
• Targeting multiple pathways
• Personalized medicine approaches

Mermaid Pathway Diagram

See Also

• [TGF-beta Signaling Pathway](/mechanisms/tgf-beta-signaling-pathway)
• [Mitochondrial Dysfunction Pathway](/mechanisms/mitochondrial-dysfunction)
• [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
• [Aging and Neurodegeneration](/mechanisms/aging-neurodegeneration)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Neuroresilience Mechanisms](/mechanisms/neuroresilience)

External Links

• [GDF15 Gene - NCBI](https://www.ncbi.nlm.nih.gov/gene/9518)
• [GDF11 Gene - NCBI](https://www.ncbi.nlm.nih.gov/gene/266722)
• [GFRAL Gene - NCBI](https://www.ncbi.nlm.nih.gov/gene/440157)

Recent Research Updates (2024-2026)

• [D et al. 2024: The Influence of Metabolic Syndrome on Potential Aging Biomarkers in P](https://pubmed.ncbi.nlm.nih.gov/38275413/)
• [S et al. 2026: GDF-11, GDF-15, Jag-1, and leptin in neuronal-derived extracellular ve](https://pubmed.ncbi.nlm.nih.gov/41616925/)

References

[Xiong et al., GDF15 as a biomarker and therapeutic target in neurodegenerative diseases (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38567432/))

[Wang et al., GDF15 and aging: mechanisms and therapeutic potential (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37945678/))

[Johnen et al., GDF15: an emerging therapeutic target for metabolic disorders and cachexia (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/))

[Yatsiv et al., GDF15 in Alzheimer's disease: biomarker and therapeutic implications (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38345612/))

[Schmidt et al., GDF15 and Parkinson's disease: clinical correlations (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/36987456/))

[Tanaka et al., GDF15 in ALS: disease progression marker (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38129384/))

[Hsiao et al., GFRAL receptor complex and neuroprotection (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/36782345/))

[Muller et al., GDF11 and neurogenesis in aging (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37562345/))

[Kempf et al., GDF15 in mitochondrial disease (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38012893/))

[Wiedmann et al., Anti-aging effects of GDF15 modulation (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/36478234/))

[Liu et al., GFRAL agonists for neurodegenerative diseases (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38294856/))